Cargando…
The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressive disease, with a median survival time of 2–5 years. The search for effective treatment has involved numerous clinical trials of investigational agents without significant success. However, in 2011, pirfenidone was the first drug to be approved for...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643400/ https://www.ncbi.nlm.nih.gov/pubmed/23734908 http://dx.doi.org/10.1186/1465-9921-14-S1-S5 |